University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)

明尼苏达大学临床与转化科学研究所 (UMN CTSI)

基本信息

  • 批准号:
    10366062
  • 负责人:
  • 金额:
    $ 577.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-03-30 至 2023-11-17
  • 项目状态:
    已结题

项目摘要

Contact PD/PI: Blazar, Bruce A. Overall: Abstract. The University of Minnesota's Clinical and Translational Science Institute's (UMN CTSI) vision is a world where impactful discoveries leading to the betterment of human health occur by bringing together Academic Health Center (AHC) research with community outreach and industry partnership. Our mission is to create a nationally-recognized, shareable model of complex translational team science driven and enabled by integration and alignment of clinical and translational science (CTS) research with education, data access, community needs, and industry efforts. In the past 6 years, CTSI 1) Developed comprehensive programs for workforce training and fostering career development for the next generation of CTS research investigators; 2) Created Community Engagement to Advance Research and Community Health (CEARCH) to support stakeholder community contributions to CTS research and to tackle health outcome disparity challenges in Somali, Latino, Native American, Hmong, and other populations; 3) Leveraged UMN research strengths and MN's vibrant biomedical industry to advance multiple projects along the commercialization pathway; and 4) Expanded its patient base from the UMN tertiary care adult and pediatric hospitals to hub partners consisting of a VA hospital, a community-based 7-hospital system, and a safety-net county hospital with 65% racial/ethnic minorities linked with i2b2/SHRINE for cohort identification. CTSI formed an unprecedented partnership with Mayo CTSA to provide statewide coverage in CTS research and education and is a founding member of the Midwest Area Research Consortium for Health, the Accrual to Clinical Trials federated cohort discovery consortium, and PCORnet Greater Plains Collaborative. To accelerate and improve CTS research and education and make lasting impacts on healthcare outcomes, we will pursue the following aims: 1. Train an outstanding multidisciplinary, diverse workforce across the CTS research spectrum skilled in and rewarded for team science using existing and new educational offerings; 2. Streamline methods and processes to increase local and national CTSI hub research capacity in a new Clinics and Surgery Center learning health system with CTSI-led research process design, CTSI's new StudyFinder tool, user-friendly IRB-approved consent form for clinical and laboratory research, bioinfor- matics tools, biospecimen collection, and a transformative Clinical Research Support Center for one-stop, single location, parallel processing of needed approvals; 3. Engage communities and stakeholders through CEARCH to improve translation and healthcare delivery across the lifespan and to a diverse population; and 4. Add unique contributions to the CTSA network by the Office of Discovery and Translation , Pediatric Device Innovation Consortium, and high and ultrahigh magnetic resonance imaging and spectroscopy applications and training. Impact. Connected to and driven by its vision and mission, CTSI will provide infrastructure and services for conducting innovative, high-impact and efficient, high-quality CTS research. Project Summary/Abstract Page 391 Contact PD/PI: Blazar, Bruce
联系PD/PI:Blazar,Bruce A.总体:摘要。明尼苏达大学的临床与转化科学学院(UMN) CTSI)是一个世界,有影响力的发现导致人类健康的改善。 通过社区外展和行业汇集学术健康中心(AHC)研究 合伙。我们的使命是创建一个全国认可的复杂翻译团队的模型 科学通过临床和转化科学(CTS)研究的整合和一致性而驱动和启用 随着教育,数据获取,社区需求和行业的努力。在过去的6年中,CTSI 1)开发 劳动力培训的全面计划,并促进下一代职业发展 CTS研究调查员; 2)创建社区参与以推进研究和社区 健康(CEARCH)支持利益相关者社区对CTS研究的贡献并解决健康 索马里,拉丁裔,美洲原住民,苗族和其他人群的结果差异挑战; 3) 利用UMN的研究优势和MN充满活力的生物医学行业,以推进多个项目 商业化途径; 4)将其患者基础从UMN三级护理成人和 由VA医院,基于社区的7院系统和一个 安全网县医院拥有65%的种族/族裔少数群体与I2B2/Shrine有联系的人群识别。 CTSI与Mayo CTSA建立了前所未有的合作伙伴关系,以在CTS中提供全州范围 研究和教育,是中西部地区健康联盟的创始成员, 对联合队列发现联盟和PCORNET更大的平原协作的临床试验应计。 为了加速和改善CTS的研究和教育,并对医疗结果产生持久的影响, 我们将追求以下目的:1。培训一支出色的多学科,多样化的劳动力 CTS研究范围使用现有和新的教育熟练并获得了团队科学的奖励 奉献; 2。简化方法和流程以提高本地和国家CTSI集线器研究能力 在新的诊所和手术中心学习健康系统中,CTSI领导的研究过程设计,CTSI的 新的LesutyFinder工具,用户友好的IRB批准同意书,用于临床和实验室研究,生物启动 原始工具,生物循环收集和一站式变革性临床研究支持中心, 单个位置,并行处理所需的批准; 3。通过 搜索以改善整个生命周期的翻译和医疗保健服务;和 4.发现与翻译办公室为CTSA网络增加独特的贡献 设备创新联盟,以及高和超高的磁共振成像和光谱 申请和培训。影响。 CTSI将与其愿景和使命相关并驱动,将提供 用于开展创新,高效和高质量CTS研究的基础设施和服务。 项目摘要/摘要页面391 联系PD/PI:Blazar,Bruce

项目成果

期刊论文数量(608)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Individual Differences in Response to Supervised Exercise Therapy for Peripheral Artery Disease.
  • DOI:
    10.1177/0193945920977479
  • 发表时间:
    2021-08
  • 期刊:
  • 影响因子:
    1.8
  • 作者:
    Whipple MO;Schorr EN;Talley KMC;Wolfson J;Lindquist R;Bronas UG;Treat-Jacobson D
  • 通讯作者:
    Treat-Jacobson D
Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis.
GMWI-webtool: a user-friendly browser application for assessing health through metagenomic gut microbiome profiling.
Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors.
  • DOI:
    10.3389/fonc.2023.1113121
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
  • 通讯作者:
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.
  • DOI:
    10.1111/apt.16013
  • 发表时间:
    2020-09
  • 期刊:
  • 影响因子:
    7.6
  • 作者:
    Prizment AE;Staley C;Onyeaghala GC;Vivek S;Thyagarajan B;Straka RJ;Demmer RT;Knights D;Meyer KA;Shaukat A;Sadowsky MJ;Church TR
  • 通讯作者:
    Church TR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce R Blazar其他文献

Mitochondrial Pyruvate Carrier Inhibition Mitigates Murine Chronic Graft Versus Host Disease By Attenuating the Germinal Center Reaction
  • DOI:
    10.1182/blood-2023-185200
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Fathima A Mohamed;Stephanie Y Rhee;Joanna Ly;Ethan G Aguilar;Haley Melin;Peter T Sage;Tanner Schumacher;Govindarajan Thangavelu;Michael C Zaiken;Juan Liu;Venkatram Mereddy;Jason W Locasale;Bruce R Blazar
  • 通讯作者:
    Bruce R Blazar
Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)
  • DOI:
    10.1182/blood-2024-205130
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Lev Gorfinkel;Muna Qayed;Brandi Bratrude;Kayla Betz;Kyle Hebert;Sung W. Choi;Jeffrey Davis;Christine Duncan;Roger H. Giller;Michael S. Grimley;Andrew Harris;David A Jacobsohn;Nahal Lalefar;Nosha Farhadfar;Michael A. Pulsipher;Shalini Shenoy;Aleksandra Petrovic;Kirk R. Schultz;Gregory Yanik;Bruce R Blazar
  • 通讯作者:
    Bruce R Blazar
Cyclosporine and Voclosporin Resistant Immune Effector Cells to Improve Outcomes after Stem Cell Transplantation
  • DOI:
    10.1182/blood-2023-180218
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Holly Wobma;Jiayi Dong;Francesca Alvarez Calderon;Xianliang Rui;Katherine Michaelis;Bruce R Blazar;Victor Tkachev;Ulrike Gerdemann;Leslie Kean
  • 通讯作者:
    Leslie Kean
IL-33 Induces Paneth Cell Production of EGF and Soluble ST2, Regulating Epithelial Regeneration after Intestinal Injury
  • DOI:
    10.1182/blood-2023-191189
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Marco Calafiore;YA-Yuan Fu;Paola Vinci;Viktor Arnhold;Winston Chang;Suze Jansen;Anastasiya Egorova;Shuichiro Takashima;Jason Kuttiyara;Takahiro Ito;Jonathan Serody;Susumu Nakae;Heth Turnquist;Johan van Es;Hans Clevers;Caroline A. Lindemans;Bruce R Blazar;Alan M. Hanash
  • 通讯作者:
    Alan M. Hanash
ACC1 Inhibition Enhances Treg Gvhd Treatment Efficacy through Regulation of Mitochondrial Fusion and Elongation
  • DOI:
    10.1182/blood-2023-187306
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Cameron McDonald-Hyman;Ethan G Aguilar;Stephanie Y Rhee;Fathima A Mohamed;Ewaldus Compeer;Timothy Sparwassar;Michael Dustin;Bruce R Blazar
  • 通讯作者:
    Bruce R Blazar

Bruce R Blazar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce R Blazar', 18)}}的其他基金

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
  • 批准号:
    10763967
  • 财政年份:
    2023
  • 资助金额:
    $ 577.8万
  • 项目类别:
In Vivo Prevention of Murine GVHD
小鼠 GVHD 的体内预防
  • 批准号:
    10362877
  • 财政年份:
    2022
  • 资助金额:
    $ 577.8万
  • 项目类别:
Metabolomics of cGVHD
cGVHD 的代谢组学
  • 批准号:
    10698171
  • 财政年份:
    2022
  • 资助金额:
    $ 577.8万
  • 项目类别:
In Vivo Prevention of Murine GVHD
小鼠 GVHD 的体内预防
  • 批准号:
    10610863
  • 财政年份:
    2022
  • 资助金额:
    $ 577.8万
  • 项目类别:
Metabolomics of cGVHD
cGVHD 的代谢组学
  • 批准号:
    10493800
  • 财政年份:
    2022
  • 资助金额:
    $ 577.8万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10560605
  • 财政年份:
    2021
  • 资助金额:
    $ 577.8万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10092348
  • 财政年份:
    2021
  • 资助金额:
    $ 577.8万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10348683
  • 财政年份:
    2021
  • 资助金额:
    $ 577.8万
  • 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
  • 批准号:
    10305635
  • 财政年份:
    2019
  • 资助金额:
    $ 577.8万
  • 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
  • 批准号:
    10656502
  • 财政年份:
    2019
  • 资助金额:
    $ 577.8万
  • 项目类别:

相似国自然基金

成人型弥漫性胶质瘤患者语言功能可塑性研究
  • 批准号:
    82303926
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
  • 批准号:
    82302160
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
  • 批准号:
    82302311
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
  • 批准号:
    82302025
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Planning grant for CMV suppression to reduce mortality in hospitalized, HIV-exposed children
为抑制巨细胞病毒(CMV)提供规划拨款,以降低感染艾滋病毒的住院儿童的死亡率
  • 批准号:
    10620961
  • 财政年份:
    2023
  • 资助金额:
    $ 577.8万
  • 项目类别:
Reducing Challenging Behaviors In Children With Autism Through Digital Health
通过数字健康减少自闭症儿童的挑战性行为
  • 批准号:
    10657558
  • 财政年份:
    2020
  • 资助金额:
    $ 577.8万
  • 项目类别:
Evaluation of Stepping Up Efforts to Improve MH Services and Justice Utilization
对加大力度改善 MH 服务和司法利用的评估
  • 批准号:
    10677888
  • 财政年份:
    2019
  • 资助金额:
    $ 577.8万
  • 项目类别:
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
  • 批准号:
    9901640
  • 财政年份:
    2018
  • 资助金额:
    $ 577.8万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9301622
  • 财政年份:
    2017
  • 资助金额:
    $ 577.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了